NGS Sequencing
Tumor tissue samples (self-blood negative control) of pan-cancer were subjected to NGS for detection the IDH1/2 mutation with 800× sequencing depth in a College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certified laboratory of 3D Medicines Inc. All pathologic or likely pathologic mutations ofIDH1/IDH2 were considered. In addition, the TMB was defined as the total number of nonsynonymous mutation in coding region. This study was conducted under the approval of the ethics committees of the hospitals and informed consents were obtained from patients.